Detalles de la búsqueda
1.
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.
Invest New Drugs
; 42(1): 127-135, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38270822
2.
Unmet Needs in Oncology Clinical Research and Treatment in Africa: Focus on Ghana.
Oncologist
; 27(9): 760-767, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35726905
3.
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Invest New Drugs
; 40(1): 115-123, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34515877
4.
A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.
Int J Cancer
; 149(12): 2063-2074, 2021 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34319586
5.
Pooled Multicenter Analysis of Cardiovascular Safety and Population Pharmacokinetic Properties of Piperaquine in African Patients with Uncomplicated Falciparum Malaria.
Antimicrob Agents Chemother
; 64(7)2020 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32312783
6.
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).
Oncologist
; 25(6): 523-531, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31872928
7.
Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals.
Crit Care Med
; 48(5): 623-633, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32141923
8.
A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
Invest New Drugs
; 38(6): 1755-1762, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32328844
9.
Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination.
Pancreatology
; 20(6): 1115-1122, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32778368
10.
Understanding, recognizing, and managing toxicities of targeted anticancer therapies.
CA Cancer J Clin
; 63(4): 249-79, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23716430
11.
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study.
Lancet Oncol
; 20(8): 1098-1108, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31255490
12.
Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
Oncologist
; 24(11): e1148-e1155, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31036771
13.
Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials.
Oncologist
; 24(1): 96-102, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30413668
14.
A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
Invest New Drugs
; 37(4): 658-665, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30382439
15.
A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.
Invest New Drugs
; 37(2): 307-314, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30171497
16.
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma.
Invest New Drugs
; 37(4): 755-762, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31172443
17.
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol
; 18(12): 1610-1623, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29129443
18.
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
Oncologist
; 22(2): 189-198, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28188257
19.
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 35(1): 47-58, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27650277
20.
New strategies to develop new medications for lung cancer and metastasis.
Cancer Metastasis Rev
; 34(2): 265-75, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25944554